Ptc Therapeutics (PTCT) Retained Earnings (2012 - 2026)

Ptc Therapeutics' Retained Earnings history runs 15 years deep, the most recent figure standing at $2.8 billion for Q1 2026.

• On a quarterly basis, Retained Earnings rose 20015.59% year-over-year to $2.8 billion in Q1 2026; TTM through Mar 2026 was $2.8 billion, a 20015.59% increase from a year earlier, with the FY2025 full-year figure at -$3.0 billion, down 11351.09% from the prior year.
• Retained Earnings rose to $2.8 billion in Q1 2026 per PTCT's latest filing, from -$3.0 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $2.8 billion in Q1 2026 and bottomed at -$3.5 billion in Q2 2024.
• The 5-year median for Retained Earnings is -$13.9 million (2025), against an average of -$444.1 million.
• Across the five-year window, Retained Earnings tumbled 242690.57% in 2024 and jumped 20015.59% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$2.7 billion in 2022, then jumped by 192.82% to $2.5 billion in 2023, then plunged by 101.05% to -$25.9 million in 2024, then plunged by 11351.09% to -$3.0 billion in 2025, then soared by 193.72% to $2.8 billion in 2026.
• Per Business Quant, the three latest PTCT Retained Earnings figures stand at $2.8 billion (Q1 2026), -$3.0 billion (Q4 2025), and $2.7 billion (Q3 2025).